Department of Head and Neck Oncology, Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France.
Department of Radiology, Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France.
Laryngoscope. 2020 Apr;130(4):E144-E150. doi: 10.1002/lary.28021. Epub 2019 Apr 22.
OBJECTIVES/HYPOTHESIS: We studied the influence of the neutrophil-to-lymphocyte ratio (NLR) and anemia on the response to induction chemotherapy (IC) and survival outcomes in laryngeal cancer patients treated with a preservation protocol.
Retrospective single-center case series.
We analyzed patients with T3 laryngeal cancer treated with IC using a preservation protocol. The NLR and hemoglobin levels were assessed before treatment and after IC. The response to chemotherapy was assessed using Response Evaluation Criteria in Solid Tumours 1.1 and World Heath Organization standards. The oncological endpoints were overall survival (OS) and disease-free survival (DFS).
Sixty-eight patients were analyzed. The median NLR and hemoglobin levels before and after IC were 2.76 and 14.5 g/dL, and 2.01 and 11.6 g/dL, respectively. The NLR and anemia before treatment were not correlated, and they were not associated with the response to chemotherapy. However, an NLR > 5 and anemia before treatment were both associated with shorter OS and DFS. Notably, they were the only factors found to be significantly associated with survival outcomes.
In laryngeal cancer, patients treated with a preservation protocol, a high NLR ratio, and anemia before IC were associated with shorter survival, independently of the response to chemotherapy.
4 Laryngoscope, 130:E144-E150, 2020.
目的/假设:我们研究了中性粒细胞与淋巴细胞比值(NLR)和贫血对采用保留方案治疗的喉癌患者诱导化疗(IC)反应和生存结果的影响。
回顾性单中心病例系列研究。
我们分析了采用 IC 保留方案治疗的 T3 喉癌患者。在治疗前和 IC 后评估 NLR 和血红蛋白水平。使用实体瘤反应评估标准 1.1 和世界卫生组织标准评估化疗反应。肿瘤学终点是总生存期(OS)和无病生存期(DFS)。
共分析了 68 例患者。IC 前后 NLR 和血红蛋白的中位数分别为 2.76 和 14.5 g/dL,2.01 和 11.6 g/dL。治疗前的 NLR 和贫血无相关性,与化疗反应无关。然而,治疗前 NLR > 5 和贫血均与 OS 和 DFS 较短相关。值得注意的是,它们是唯一与生存结果显著相关的因素。
在采用保留方案治疗的喉癌患者中,IC 前 NLR 比值高和贫血与生存时间较短有关,与化疗反应无关。
4《喉镜》,130:E144-E150,2020 年。